Alliancebernstein L.P. Arbutus Biopharma Corp Transaction History
Alliancebernstein L.P.
- $290 Billion
- Q2 2025
A detailed history of Alliancebernstein L.P. transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Alliancebernstein L.P. holds 120,240 shares of ABUS stock, worth $581,961. This represents 0.0% of its overall portfolio holdings.
Number of Shares
120,240
Previous 120,240
-0.0%
Holding current value
$581,961
Previous $419,000
11.46%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding ABUS
# of Institutions
184Shares Held
118MCall Options Held
1MPut Options Held
478K-
Morgan Stanley New York, NY24.2MShares$117 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY13.3MShares$64.6 Million14.31% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$55.9 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY10.4MShares$50.5 Million0.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.09MShares$44 Million0.0% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $726M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...